A dual antigen ELISA allows the assessment of SARS-CoV-2 antibody seroprevalence in a low transmission setting

    Thumbnail
    Download
    Citations
    Altmetric
    Author
    Hicks, S; Pohl, K; Neeman, T; McNamara, H; Parsons, K; He, J-S; Ali, S; Nazir, S; Rowntree, L; Nguyen, T; ...
    Date
    2020-09-14
    Source Title
    medRxiv
    Publisher
    Cold Spring Harbor Laboratory
    University of Melbourne Author/s
    George, Amee; Kedzierska, Katherine; Nguyen, Thi Hoang Oanh
    Affiliation
    Clinical Pathology
    Metadata
    Show full item record
    Document Type
    Preprint
    Citations
    Hicks, S., Pohl, K., Neeman, T., McNamara, H., Parsons, K., He, J. -S., Ali, S., Nazir, S., Rowntree, L., Nguyen, T., Kedzierska, K., Doolan, D., Vinueas, C., Cook, M., Coatsworth, N., Myles, P., Kurth, F., Sander, L., Mann, G. ,... the SARS-CoV-2 Testing in Elective Surgery Collaborators, (2020). A dual antigen ELISA allows the assessment of SARS-CoV-2 antibody seroprevalence in a low transmission setting. medRxiv, https://doi.org/10.1101/2020.09.09.20191031.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/253073
    DOI
    10.1101/2020.09.09.20191031
    Abstract
    Estimates of seroprevalence of SARS-CoV-2 antibodies have been hampered by inadequate assay sensitivity and specificity. Using an ELISA-based approach to that combines data about IgG responses to both the Nucleocapsid and Spike-receptor binding domain antigens, we show that near-optimal sensitivity and specificity can be achieved. We used this assay to assess the frequency of virus-specific antibodies in a cohort of elective surgery patients in Australia and estimated seroprevalence in Australia to be 0.28% (0 to 0.72%). These data confirm the low level of transmission of SARS-CoV-2 in Australia before July 2020 and validate the specificity of our assay.

    Export Reference in RIS Format     

    Publisher licence
    CC BY-NC-ND
    Collections